MedTrace Logo

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

NCT04405375 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2020-05-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).

Conditions

  • Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG

gemcitabin

1.25g/㎡ d1, repeated every 21 days

DRUG

Pegaspargase

2500IU/㎡ d1, total dose=\<3750IU, repeated every 21 days

DRUG

Etoposide

75mg/㎡ d1-3, repeated every 21 days

DRUG

Dexamethasone

20mg d1-4

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-21
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405375 on ClinicalTrials.gov